<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Vismodegib</strong></td></tr><tr><th>Accession Number</th><td><strong>DB08828</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Vismodegib inhibits the hedgehog signalling pathway and is indicated for treatment of adult basal cell carcinoma. <span class="caps">FDA</span> approved on Jan 30, 2012.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB08828/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB08828/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08828.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08828.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08828.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08828.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08828.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB08828">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>GDC-0449</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Hedgehog Antagonist GDC-0449</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Erivedge</td><td>Genentech</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>879085-55-9</td></tr><tr><th>Weight</th><td>Average: 421.297<br>Monoisotopic: 420.010218428</td></tr><tr><th>Chemical Formula</th><td>C<sub>19</sub>H<sub>14</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>3</sub>S</td></tr><tr><th>InChI Key</th><td>BPQMGSKTAYIVFO-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-methanesulfonylbenzamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CS(=O)(=O)C1=CC(Cl)=C(C=C1)C(=O)NC1=CC=C(Cl)C(=C1)C1=CC=CC=N1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Benzamides</td></tr><tr><th>Direct parent</th><td>N-phenylbenzamides</td></tr><tr><th>Alternative parents</th><td>Phenylpyridines; Anilides; Benzoyl Derivatives; Chlorobenzenes; Aryl Chlorides; Sulfones; Sulfoxides; Secondary Carboxylic Acid Amides; Carboxylic Acids; Enolates; Polyamines; Organochlorides</td></tr><tr><th>Substituents</th><td>2-phenylpyridine; acetanilide; benzoyl; chlorobenzene; pyridine; aryl chloride; aryl halide; sulfone; sulfonyl; secondary carboxylic acid amide; carboxamide group; sulfoxide; polyamine; enolate; carboxylic acid; carboxylic acid derivative; organohalogen; amine; organochloride; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the n-phenylbenzamides.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Vismodegib is used for treating locally advanced or metastatic basal cell carcinoma in patients whose carcinoma has recurred after surgery, and in patients who are not candidates for surgery or radiation.</td></tr><tr><th>Pharmacodynamics</th><td>Vismodegib selectively binds to and inhibits the transmembrane protein Smoothened homologue (SMO) to inhibit the Hedgehog signalling pathway. </td></tr><tr><th>Mechanism of action</th><td>Mutations of the Hedgehog pathway may results in uncontrolled proliferation of skin basal cells. Vismodegib binds to and inhibits the transmembrane protein Smoothened homologue (SMO) to inhibit the Hedgehog signalling pathway. </td></tr><tr><th>Absorption</th><td>The absolute bioavailability of a single dose is 31.8%. Absorption is saturable and is not affected by food. </td></tr><tr><th>Volume of distribution</th><td><p>Vismodegib has a volume of distribution of 16.4 to 26.6 L.</p></td></tr><tr><th>Protein binding</th><td>Vismodegib is highly protein bound with plasma protein binding at about 99%. Vismodegib binds to the plasma proteins, albumin and alpha-1-acid glycoprotein (saturable bnding).</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>The main metabolic enzymes are CYP2C9 and CYP3A4, however more than 98% of total systemic vismodegib is not metabolized. Metabolic pathways of vismodegib in humans include oxidation, glucuronidation, and pyridine ring cleavage. The two most abundant oxidative metabolites recovered in feces are produced in vitro by recombinant CYP2C9 and CYP3A4/5.</p></td></tr><tr><th>Route of elimination</th><td>Vismodegib is mostly excreted unchanged, and the main route of elimination is by the feces (82%) and the urine accounts for 4.4%.</td></tr><tr><th>Half life</th><td>The half-life after a single dose is 12 days, and after continuous daily dosing is 4 days.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Increased risk of embryo-fetal death and significant birth defects. Common adverse event include muscle spasms, alopecia, dysgeusia, weight loss, fatigue, nausea, diarrhea, decreased appetite, constipation, arthralgias, vomiting, and ageusia. </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9547</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9387</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.6048</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.8443</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8663</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9558</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8925</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.6009</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.63</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5083</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6067</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Inhibitor</td>
        <td>0.9078</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6638</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.8515</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.8452</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.9282</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8271
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.6746
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9956
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.0840 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9973
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8224
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td>150 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00207">Azithromycin</a></td><td>P-glycoprotein inhibitors may increase the chance of adverse drug reactions. </td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>P-glycoprotein inhibitors may increase the chance of adverse drug reactions. </td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>P-glycoprotein inhibitors may increase the chance of adverse drug reactions. </td></tr><tr><td><a href="/drugs/DB08820">Ivacaftor</a></td><td>P-glycoprotein inhibitors may increase the chance of adverse drug reactions. Consider using alternative therapy. </td></tr><tr><td><a href="/drugs/DB00338">Omeprazole</a></td><td>Vismodegib serum concentrations may be decreased by proton pump inhibitors such as omeprazole.</td></tr><tr><td><a href="/drugs/DB00863">Ranitidine</a></td><td>Vismodegib serum concentrations may be decreased by histamine 2 receptor antagonists such as ranitidine.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Food does not affect absorption.</li></ul></td></tr></tbody></table>